Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors.
In 2020, revenues reached €3.1 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety.
Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
-
Industry
-
Biotechnology Research
-
Company size
-
10,001+ employees
-
Headquarters
-
Marcy-l'Étoile, Auvergne-Rhône-Alpes
-
Type
-
Public Company
-
Founded
-
1963
-
Specialties
-
in vitro diagnostics, infectious diseases, reagents, automated instruments, medical analysis, cosmetics, pharmaceutical, industries, healthcare associated infections, molecular biology, microbiology, immunoassays, antimicrobial stewardship, rapid diagnostics, food safety, veterinary diagnostics, blood bank, and sepsis
